The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
.
Recent Transactions
Sort By
10-Aug-23
Undisclosed
Target:
Clinigen Ltd’s portfolio of Established Medicines
Acquiror:
CNX Therapeutics
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners
13-Jul-23
$224 million
Target:
Distribuidora Internacional Carmen SAU
Acquiror:
Diploma PLC
Advised Diploma PLC in the acquisition of Distribuidora Internacional Carmen SAU (“DICSA”), a market-leading distributor of fluid power solutions into the European aftermarket
01-Jun-23
$90.4 million
Target:
PCAS Canada Inc.
Acquiror:
DIC Corporation
Advised DIC Corporation, a Japanese specialty chemical company, on the acquisition of PCAS Canada Inc., a contract manufacturer of high-quality photoresist polymers, from PCAS SA, a French manufacturer of complex molecules for Life Sciences and Specialty Chemicals markets which is a majority-owned subsidiary of SK Capital-backed Seqens
27-Apr-23
$403 million
Target:
Distrelec BV
Acquiror:
RS Group plc
Advised RS Group plc on the acquisiton of Distrelec, a high-service, digital-led distributor of industrial MRO and electronic products
25-Apr-23
Pending
Undisclosed
Target:
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Acquiror:
Advanz Pharma (UK)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
20-Mar-23
Pending
Undisclosed
Target:
Clinigen Ltd’s Lamda Laboratories
Acquiror:
Adragos Pharma
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
07-Mar-23
Undisclosed
Target:
David Brown Santasalo
Acquiror:
Stellex Capital Management
Advised N4 Partners on the sale of David Brown Santasalo (DBS), UK based industrial gear manufacturer, to Stellex Capital Management
23-Jan-23
Pending
$200 million
Target:
Clinigen Ltd’s Proleukin
Acquiror:
Iovance Biotherapeutics
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
28-Dec-22
Pending
Undisclosed
Target:
Eisai Distribution Co., Ltd.
Acquiror:
Yasuda Logistics Corporation
Advising Eisai, a Japanese pharmaceutical company, on the sale of Eisai Distribution, a 100% shares holding logistic subsidiary, to Yasuda Logistics Corporation, a Japanese logistic company conducting total logistic services such as Warehousing, Transportation, delivery and forwarding, and Port transportation business, etc.
16-Dec-22
Pending
$165 million
Target:
Portfolio of Towers from PLDT
Acquiror:
Unity Digital Infrastructure Inc. (JV between Partners Group and Aboitiz InfraCapital)
Advising Unity Digital Infrastructure Inc., a leading Philippine-based joint venture telecommunications infrastructure platform by Aboitiz InfraCapital and Partners Group, on the acquisition of 650 towers from PLDT, one of the largest telecommunication service providers in the Philippines, through a sale and leaseback transaction
28-Nov-22
Pending
$650 million
Target:
Brambles (CHEP China)
Acquiror:
Loscam Greater China
Adviser to Brambles on the merger of its China business (CHEP China) with Loscam Greater China
24-Nov-22
Pending
Undisclosed
Target:
Kyowa Kirin International’s established medicines business
Acquiror:
Grünenthal
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
13-Sep-22
Undisclosed
Target:
InterGen N.V.’s UK business
Acquiror:
Bortela Capital s.r.o
Advised InterGen N.V., one of the UK’s largest independent power producers with a portfolio of four gas plants and a pipeline of large-scale battery energy storage system projects, on the sale of its business interests in the UK to CREDITAS Group, a Czech entity ultimately owned by Pavel Hubáček, whose energy division UCED is the fourth largest energy distributor in the Czech Republic
02-Sep-22
Pending
$205 million
Target:
brsk
Acquiror:
Ares Management
Advising brsk, a UK-based alternative network broadband provider, on its first debt-raise of £178m from Ares Management, a leading global alternative investment manager
28-Jul-22
Pending
$1.6 billion
Target:
Derco Holdings
Acquiror:
Inchcape Plc
Advising and acting as sponsor to Inchcape plc, the leading independent global automotive distributor, on its proposed Class 1 acquisition of Derco, the largest independent automotive distributor by volume in Latin America
04-Jul-22
$270 million
Target:
Vulcanic
Acquiror:
Spirax-Sarco Engineering plc
Advised Spirax-Sarco Engineering plc, a thermal energy management and niche pumping specialist, on the $270m acquisition of Vulcanic, a French industrial electric heating group and the largest supplier in Europe of bespoke industrial electric heating solutions
19-Apr-22
Pending
$800 million
Target:
Portfolio of Towers from PLDT
Acquiror:
edotco Group
Advising edotco Group, the leading pan-Asian telecom tower infrastructure company, on the acquisition of 2,973 towers from PLDT, one of the largest telecommunication service providers in the Philippines, through a sale and leaseback transaction
28-Mar-22
Pending
~$1.4 billion
Target:
Theramex
Acquiror:
Carlyle and PAI Partners
Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners
28-Mar-22
Pending
$105 million
Target:
Acacia Pharma Group plc
Acquiror:
Eagle Pharmaceuticals, Inc.
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
07-Dec-21
$153 million
Target:
Japan Medical Dynamic Marketing
Acquiror:
Mitsui Chemicals
Advising Mitsui Chemicals, one of the largest Japanese chemical companies, on the acquisition of a 30% stake in Japan Medical Dynamic Marketing, a leading orthopedic medical device manufacturer in Japan, held by NGK SPARK PLUG
05-Oct-21
$175 million
Target:
Kao Data Ltd
Acquiror:
Infratil Ltd
Advised Kao Data Ltd, which is jointly owned by Legal & General Group PLC and Noé Group subsidiary Hockham, on raising an initial £120m-£130m growth capital commitment from Infratil Ltd with the objective of creating a £500m data centre platform
09-Sep-21
$2.1 billion
Target:
easyJet plc
Acquiror:
N/A
Advising and acting as joint sponsor to UK-based easyJet plc, a leading low-cost European airline carrier, on its £1.2bn fully underwritten rights issue & $400m secured RCF
27-Jul-21
Undisclosed
Target:
Pulsant Limited
Acquiror:
Antin Infrastructure Partners
Advised Antin Infrastructure Partners on its acquisition of Pulsant from Oak Hill and Scottish Equity Partners. Pulsant is a hybrid cloud specialist, with a nationwide network of 10 data centres across the UK delivering secure, scalable and resilient cloud, colocation and networking services
14-Jul-21
Undisclosed
Target:
New Day Aluminum LLC
Acquiror:
Concord Resources Ltd.
Advised DADA Holdings on the sale of its majority stake in New Day Aluminum LLC to Concord Resources Ltd.
01-Jul-21
$180 million
Target:
British Council’s Indian IELTS operations
Acquiror:
IDP Education Limited
Sole financial adviser to IDP Education, a co-owner and distributor of the IELTS English language test, on the acquisition of the British Council’s Indian IELTS operations